Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 1997

View Archived Issues

Company Profile: Cell Therapeutics

Synsorb Biotech: nine-month 1997 highlights

British Biotech: Q2 and HY 1997/98 highlights

Inex: Q3 1997 highlights

ImClone Systems' C225 enters phase II for metastatic renal cell carcinoma

Algene: Q3 1997 highlights

Protein farnesyltransferase inhibitors focus of research at Merck & Co.

3-Dimensional Pharmaceuticals discloses new serine protease inhibitors

Agents for HCV infection from ViroPharma

Novel antithrombotic agent developed at Otsuka

Potential new male contraceptive under development in China

E-5531: a synthetic endotoxin antagonist developed at Eisai

Preclinical and preliminary clinical profile of NE-100, a new antipsychotic drug

Potent and selective dopamine D4 antagonist discovered at Yamanouchi

Yamanouchi describes SAR leading to YM-60828, a potent and selective factor Xa inhibitor

Profile of novel topoisomerase II inhibitor, ER-37328, from Eisai

SAR and biological profile of FR-86521, a cephalosporin highly active against MRSA

Meiji Seika presents new carbapenem derivatives

MKT-077: a novel antitumor rhodacyanine dye in clinical testing

Fujisawa discovers new triazole antifungals with excellent oral activity

New indication for Neutralase revealed

FDA approves SERM for preventing postmenopausal osteoporosis

Integrilin to be reviewed by FDA advisory panel

Cel-Sci AIDS vaccine effective in mouse model of HIV and immunogenic in humans

FDA approves Neoprobe's IND for RIGS/ACT therapy

Emisphere and Novartis sign agreement for drug delivery research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...